Snail Toxin For Developing Drugs Against Neurological Disorders

Filed in archive Drugs, Vaccines and Therapeutics , Genomics, Proteomics and Bioinformatics on August 21, 2006

Scientists have been able to isolate a "conotoxin", a peptide from the venomous Cone snail Conus omaria (photo) that seems to block the nicotine receptors in the brain. While the obvious application may be as a drug candidate to help patients to quit smoking, its discoverers say the toxin may also have other uses as a tool in developing drugs for other neurological diseases such as Alzheimer's, Parkinson's, depression, and perhaps even schizophrenia.

McIntosh says the new toxin itself is unlikely to become a drug because it blocks rather than stimulates nicotinic receptors. But because it can act on some types of nicotinic receptors and not others - like a key that opens some locks but not others - it has great potential as a tool for precisely identifying the shape and structure of the receptor "locks," thus making it easier to design new medicines or "keys" to fit those receptors and trigger them to release desired neurotransmitters.

See the full article from the Brain Institute at the University of Utah on how the toxin were isolated from venomous snails collected in the Philippines, and other details of the study.

[Photo: A shell from the venomous cone snail Conus omaria, which lives in the Pacific and Indian oceans and eats other snails. Credit: Kerry Matz]